Replies to post #119661 on Biotech Values

[biomaven0]

The study showed a 9 percent reduction in the rate of overall confirmed low levels of blood sugar for Degludec compared to Lantus and a 26 percent reduction in rate of nocturnal confirmed levels of low blood sugar for Degludec compared to Lantus

I suspect they will now run a study where they equalize hypoglycemia rates and show an improved HbA1c instead, because that's really what drives sales. (Not saying it should be what drive sales - my view is that reducing episodes of hypoglycemia is likely much more important than reducing HbA1c below say 7%).

I'm a long term holder of NVO - they are my only significant pharma holding.

Peter